AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15042673 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (PSA testing)
Number of subjects: 10000
Study 11497016 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT+)
Number of subjects: 16
Study 11497016 — intervention group
Group type: COMPARATOR
Intervention: Steroid and/or anapolan treatment (BMT-)
Number of subjects: 16
Study 7871339 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (doctors offered a WHO textbook on drug prescription and three monthly meetings with nurses and social workers)
Number of subjects: 340
Study 7871339 — intervention group
Group type: COMPARATOR
Intervention: Control group (doctors not offered the WHO textbook or meetings)
Number of subjects: 340
Study 2829371 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg twice a day for 1 day
Number of subjects: 0
Study 2829371 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg twice a day for 2 days
Number of subjects: 0
Study 2829371 — intervention group
Group type: COMPARATOR
Intervention: Oral ketoconazole and vaginal econazole nitrate (control)
Number of subjects: 0
Study 31840332 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to promote symptom management and self-care
Number of subjects: 349
Study 29551222 — intervention group
Group type: EXPERIMENTAL
Intervention: High-VF diet
Number of subjects: 0
Study 28188149 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayered guideline presentation format
Number of subjects: 181
Study 28188149 — intervention group
Group type: COMPARATOR
Intervention: Standard narrative presentation format
Number of subjects: 181
Study 28188149 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayered format
Number of subjects: 181
Study 28188149 — intervention group
Group type: COMPARATOR
Intervention: Standard format
Number of subjects: 181
Study 24961447 — intervention group
Group type: EXPERIMENTAL
Intervention: Kochujang (34.5 g/d)
Number of subjects: 30
Study 24961447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24198754 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg or 2 mg oromucosal nicotine spray
Number of subjects: 31
Study 24198754 — intervention group
Group type: COMPARATOR
Intervention: Placebo oromucosal nicotine spray
Number of subjects: 31
Study 24198754 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (1 mg or 2 mg)
Number of subjects: 31
Study 21624391 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 0, 3, or 6 mg daily for six consecutive days
Number of subjects: 0
Study 21624391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17407823 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ms presentation duration for phonologically associated lists
Number of subjects: 0
Study 17407823 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ms presentation duration for phonologically associated lists
Number of subjects: 0
Study 17407823 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ms and 50 ms presentation durations for semantically associated lists
Number of subjects: 0
Study 17407823 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero correct recall condition for phonologically associated lists
Number of subjects: 0
Study 16495359 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual illusions affecting precision grasping with the left hand in left-handed subjects.
Number of subjects: 0
Study 16495359 — intervention group
Group type: COMPARATOR
Intervention: Visual illusions affecting precision grasping with the right hand in right-handed subjects.
Number of subjects: 0
Study 16495359 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural setting precision grasping in left-handed subjects using their nondominant (right) hand.
Number of subjects: 0
Study 14966574 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy at a pressure of 0.25 MPa
Number of subjects: 30
Study 14966574 — intervention group
Group type: COMPARATOR
Intervention: Control group (gargle)
Number of subjects: 30
Study 10881250 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/d
Number of subjects: 636
Study 10881250 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 32 mg/d
Number of subjects: 636
Study 10881250 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/d and 32 mg/d
Number of subjects: 636
Study 9008256 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Fosinopril + 12.5 mg Hydrochlorothiazide
Number of subjects: 550
Study 9008256 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Fosinopril + 12.5 mg Hydrochlorothiazide
Number of subjects: 550
Study 12959315 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazinaclone (DN‐2327) 4 mg
Number of subjects: 0
Study 12959315 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazinaclone (DN‐2327) 8 mg
Number of subjects: 0
Study 12959315 — intervention group
Group type: EXPERIMENTAL
Intervention: Active metabolite MII
Number of subjects: 0
Study 12959315 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazinaclone (DN‐2327) and MII
Number of subjects: 0
Study 3611334 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental treatment (intensive physical therapy course for 6 weeks)
Number of subjects: 12
Study 29452134 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) - 4 x 4 min bouts at 85-95% HRmax, 3 times/week
Number of subjects: 99
Study 29452134 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training (MICT) - 44 min at 60-70% HRmax, 3 times/week
Number of subjects: 99
Study 29452134 — intervention group
Group type: COMPARATOR
Intervention: Nutrition advice only
Number of subjects: 99
Study 27395413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic confinement combined with daily moderate-intensity exercise (HAMB)
Number of subjects: 11
Study 27395413 — intervention group
Group type: COMPARATOR
Intervention: Bed rest in normoxia (NBR)
Number of subjects: 11
Study 27395413 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest in hypoxia (HBR)
Number of subjects: 11
Study 26248510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rVSV-ZEBOV (3×10^5 pfu)
Number of subjects: 56
Study 26248510 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rVSV-ZEBOV (1×10^7 pfu or 5×10^7 pfu)
Number of subjects: 56
Study 26248510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 24183475 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week fundamental motor skill programme (20 sessions of 60 minutes each, 2 per week)
Number of subjects: 93
Study 24183475 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week fundamental motor skill programme
Number of subjects: 93
Study 24183475 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional practice)
Number of subjects: 93
Study 21387109 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-5T4 (TroVax(®))
Number of subjects: 733
Study 21387109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study 18250971 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8+ T cells expressing CD45RO
Number of subjects: 0
Study 18250971 — intervention group
Group type: COMPARATOR
Intervention: CD3+ T cells expressing activation marker CD25
Number of subjects: 0
Study 18250971 — intervention group
Group type: COMPARATOR
Intervention: CD4+ T cells expressing memory marker CD45RO
Number of subjects: 0
Study 16633098 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride
Number of subjects: 20
Study 16633098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12594139 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide at 50% FE'(N(2)O)
Number of subjects: 10
Study 12594139 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.025, 0.05 and 0.1 micro g kg(‐1) min(‐1))
Number of subjects: 10
Study 12594139 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide at 20% FE'(N(2)O)
Number of subjects: 10
Study 12594139 — intervention group
Group type: COMPARATOR
Intervention: Pain (control condition)
Number of subjects: 10
Study 10955754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen at 2 l min(‐1)
Number of subjects: 10
Study 10955754 — intervention group
Group type: COMPARATOR
Intervention: Sham oxygen (carrying the portable oxygen cylinder and breathing air)
Number of subjects: 10
Study 10955754 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS at 14 cmH2O from a portable ventilator (the HIPPY)
Number of subjects: 10
Study 10955754 — intervention group
Group type: COMPARATOR
Intervention: Baseline walk (no assistance)
Number of subjects: 10
Study 10955754 — intervention group
Group type: COMPARATOR
Intervention: Sham IPS (< 8 cmH2O)
Number of subjects: 10
Study 8839325 — intervention group
Group type: EXPERIMENTAL
Intervention: Companion bird (experimental group, n = 20)
Number of subjects: 40
Study 8839325 — intervention group
Group type: COMPARATOR
Intervention: No companion bird (control group, n = 20)
Number of subjects: 40
Study 8398588 — intervention group
Group type: EXPERIMENTAL
Intervention: R-verapamil 500 mg
Number of subjects: 0
Study 8398588 — intervention group
Group type: EXPERIMENTAL
Intervention: R-verapamil 1000 mg
Number of subjects: 0
Study 8398588 — intervention group
Group type: EXPERIMENTAL
Intervention: R-verapamil 250 mg
Number of subjects: 0
Study 8398588 — intervention group
Group type: COMPARATOR
Intervention: 240 mg racemic verapamil
Number of subjects: 0
Study 8398588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3533370 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral nalmefene
Number of subjects: 0
Study 3533370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29577496 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (1 mA)
Number of subjects: 30
Study 29577496 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study 26606735 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily for 24 months plus ASA ≤100 mg for one month
Number of subjects: 16000
Study 26606735 — intervention group
Group type: COMPARATOR
Intervention: Conventional dual antiplatelet therapy (DAPT) with either ticagrelor or clopidogrel for 12 months plus ASA ≤100 mg for 24 months
Number of subjects: 16000
Study 24276953 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (day 1: 125 mg; days 2-3: 80 mg)
Number of subjects: 421
Study 24276953 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (days 1-3: placebo)
Number of subjects: 421
Study 22774396 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with myo-inositol (MI) and D-chiro-inositol (DCI)
Number of subjects: 50
Study 22774396 — intervention group
Group type: COMPARATOR
Intervention: Myo-inositol (MI) alone
Number of subjects: 50
Study 20672368 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted physical activity (APA) sessions during hospitalization
Number of subjects: 30
Study 20672368 — intervention group
Group type: COMPARATOR
Intervention: Hospital stay without APA sessions
Number of subjects: 30
Study 18301345 — intervention group
Group type: EXPERIMENTAL
Intervention: Transluminal balloon angioplasty (TBA) on middle cerebral artery territories (n = 57 vessel segments)
Number of subjects: 38
Study 18301345 — intervention group
Group type: COMPARATOR
Intervention: Control group (anterior cerebral artery territories not subjected to TBA, n = 61 vessel segments)
Number of subjects: 38
Study 15986825 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 0
Study 15986825 — intervention group
Group type: EXPERIMENTAL
Intervention: Life exhaustion
Number of subjects: 0
Study 15986825 — intervention group
Group type: EXPERIMENTAL
Intervention: Low index of close relation
Number of subjects: 0
Study 15986825 — intervention group
Group type: EXPERIMENTAL
Intervention: Low index of social relations
Number of subjects: 0
Study 15986825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbance
Number of subjects: 0
Study 15986825 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful events in the family
Number of subjects: 0
Study 15986825 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressful events at the job
Number of subjects: 0
Study 15986825 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of hostility
Number of subjects: 0
Study 15986825 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative psychosocial factors (e.g., being a widower, divorced, low education, manual labor, pensioners, low social support)
Number of subjects: 0
Study 12865375 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral training
Number of subjects: 200
Study 12865375 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral training plus PFES
Number of subjects: 200
Study 12865375 — intervention group
Group type: COMPARATOR
Intervention: Self‐administered behavioral treatment using a self‐help booklet (control condition)
Number of subjects: 200
Study 12865375 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 200
Study 10369612 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 10 mg tablet
Number of subjects: 76
Study 10369612 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ 12.5 mg tablet
Number of subjects: 76
Study 10369612 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet of fosinopril 10 mg plus HCTZ 12.5 mg
Number of subjects: 76
Study 10369612 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministered tablets of fosinopril 10 mg and HCTZ 12.5 mg
Number of subjects: 76
Study 10369612 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg tablet
Number of subjects: 76
Study 10369612 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet of fosinopril 20 mg plus HCTZ 12.5 mg
Number of subjects: 76
Study 10369612 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministered tablets of fosinopril 20 mg and HCTZ 12.5 mg
Number of subjects: 76
Study 8675554 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/day Tibolone
Number of subjects: 91
Study 8675554 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day Tibolone
Number of subjects: 91
Study 8675554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 1839111 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter interventions (stretching of the stenosis)
Number of subjects: 0
Study 1839111 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter recanalization of the femoral artery
Number of subjects: 0
Study 1839111 — intervention group
Group type: COMPARATOR
Intervention: Endogenous risk factors vs smoking
Number of subjects: 0
Study 1839111 — intervention group
Group type: COMPARATOR
Intervention: Stenoses of the iliac artery
Number of subjects: 0
Study 6148621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400-800 mg/day)
Number of subjects: 83
Study 6148621 — intervention group
Group type: COMPARATOR
Intervention: Parietal-cell vagotomy (PCV)
Number of subjects: 83
Study 6148621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine or PCV
Number of subjects: 83
Study 30207041 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-min outdoor time/day
Number of subjects: 6295
Study 30207041 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-min outdoor time/day
Number of subjects: 6295
Study 30207041 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6295
Study 29321687 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified maize consumption
Number of subjects: 679
Study 27463113 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour rest after sheath removal
Number of subjects: 730
Study 27463113 — intervention group
Group type: COMPARATOR
Intervention: 5-hour rest after sheath removal
Number of subjects: 730
Study 24549963 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg imatinib tablet
Number of subjects: 28
Study 24549963 — intervention group
Group type: COMPARATOR
Intervention: 2×100-mg imatinib tablets
Number of subjects: 28
Study 22371023 — intervention group
Group type: COMPARATOR
Intervention: fs-laser therapy (simulated with modified contact lenses)
Number of subjects: 27
Study 22371023 — intervention group
Group type: COMPARATOR
Intervention: Modified lenses with a regular grid pattern
Number of subjects: 27
Study 22371023 — intervention group
Group type: COMPARATOR
Intervention: Randomly chosen spacing of laser spots
Number of subjects: 27
Study 20167668 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued supervised exercise (EX)
Number of subjects: 102
Study 20167668 — intervention group
Group type: COMPARATOR
Intervention: No exercise (NoEX)
Number of subjects: 102
Study 20167668 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (supervised walking/jogging at 60% Vo(2 max), -400 kcal/session, 5 days/wk, and caloric restriction -600 kcal/day for 4-6 months)
Number of subjects: 102
Study 20167668 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight regain (+50% of lost weight for 4-6 months)
Number of subjects: 102
Study 18391051 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cognitive-behavioral treatment (CBT)
Number of subjects: 100
Study 18391051 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral treatment (CBT)
Number of subjects: 100
Study 18391051 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioral treatment (CBT)
Number of subjects: 100
Study 16033489 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient safety training intervention (two workshops over a 6-month period)
Number of subjects: 356
Study 16033489 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 356
Study 12447271 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 12447271 — intervention group
Group type: COMPARATOR
Intervention: ERCP
Number of subjects: 0
Study 12447271 — intervention group
Group type: COMPARATOR
Intervention: Overall survival, relief of jaundice, technical success, total hospitalization days, or perioperative mortality
Number of subjects: 0
Study 10069782 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methionine (L‐methionine 100 mg/kg)
Number of subjects: 17
Study 10069782 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methionine preceded by vitamin C (1g/day, for 1 week)
Number of subjects: 17
Study 10069782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7745364 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation at 3 Hz
Number of subjects: 7
Study 7745364 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation at 9 Hz
Number of subjects: 7
Study 2149673 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of etodolac
Number of subjects: 36
Study 2149673 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 mg of etodolac
Number of subjects: 36
Study 2149673 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac
Number of subjects: 36
Study 6130557 — intervention group
Group type: EXPERIMENTAL
Intervention: Destyrosine-gamma-endorphin (DTGE) high doses (20-120 mg)
Number of subjects: 4
Study 6130557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31999876 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic resistance training (48 supervised sessions over 4 months)
Number of subjects: 87
Study 31999876 — intervention group
Group type: COMPARATOR
Intervention: Usual level of physical activity (Control)
Number of subjects: 87
Study 30932953 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART arm
Number of subjects: 3438
Study 30932953 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART arm
Number of subjects: 3438
Study 28132876 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-Enhanced Coaching (TEC)
Number of subjects: 290
Study 28132876 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Coaching alone
Number of subjects: 290
Study 28132876 — intervention group
Group type: COMPARATOR
Intervention: Observational Control group
Number of subjects: 290
Study 25901548 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal blanket group
Number of subjects: 80
Study 25901548 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 23313532 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus manual therapy
Number of subjects: 206
Study 23313532 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus exercise therapy
Number of subjects: 206
Study 23313532 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus combined exercise therapy and manual therapy
Number of subjects: 206
Study 23313532 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 206
Study 23313532 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance tests
Number of subjects: 206
Study 22108471 — intervention group
Group type: EXPERIMENTAL
Intervention: Viatromb (heparin spraygel 2.400 IU/g)
Number of subjects: 0
Study 22108471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19728560 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (CYP acetate 2 mg tablet with ethinylestradiol 0.25 mg)
Number of subjects: 44
Study 19728560 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (CYP acetate 2 mg tablet with ethinylestradiol 0.25 mg)
Number of subjects: 44
Study 17716314 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical (NS)
Number of subjects: 60
Study 17716314 — intervention group
Group type: COMPARATOR
Intervention: Surgical (SG)
Number of subjects: 60
Study 17716314 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical plus enamel matrix protein derivative (S+EMD)
Number of subjects: 60
Study 15242562 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemp.desensitizer without acid-etch (group NE)
Number of subjects: 91
Study 15242562 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemp.desensitizer with acid-etch (group E)
Number of subjects: 91
Study 11496446 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief couple therapy intervention (2 to 4 sessions)
Number of subjects: 19
Study 11496446 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 19
Study 9517520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg three times daily for 3 days)
Number of subjects: 19